

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON 12 JUNE 2026
AND
APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

References are made to the circular (the “**Circular**”) and the notice of annual general meeting (the “**Notice of 2026 AGM**”) dated 28 April 2026 of SinoMab BioScience Limited (the “**Company**”). Unless the content otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE 2026 AGM

As at the date of the 2026 AGM, the total number of Shares of the Company in issue was 1,386,638,336 Shares, which was the total number of Shares entitling the holders thereof to attend and vote on the resolutions at the 2026 AGM. As at the date of the 2026 AGM, the Company did not hold any treasury shares (including any treasury shares held or deposited with the Central Clearing and Settlement System).

There were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions at the 2026 AGM as set out in Rule 13.40 of the Listing Rules, nor any shareholders of the Company required under the Listing Rules to abstain from voting on any of the resolutions at the 2026 AGM. None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the 2026 AGM.

All of the Directors were present at the meeting either in person or by way of electronic means.

The Company’s share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the poll taken at the 2026 AGM.

The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended 31 December 2025.	288,465,357 (100.000000%)	0 (0.000000%)
2(a).	To re-elect Dr. Chi Ming LEE as an independent non-executive director of the Company.	288,465,357 (100.000000%)	0 (0.000000%)
2(b).	To re-elect Dr. Jianmin ZHANG as a non-executive director of the Company.	288,465,357 (100.000000%)	0 (0.000000%)
2(c).	To re-elect Ms. Chi Sau Giselle LEE as an independent non-executive director of the Company.	288,465,357 (100.000000%)	0 (0.000000%)
2(d).	To re-elect Mr. Nan SHEN as an independent non-executive director of the Company.	288,465,357 (100.000000%)	0 (0.000000%)
2(e).	To authorise the board of directors to fix the respective directors' remuneration.	288,465,357 (100.000000%)	0 (0.000000%)
2(f).	To elect Ms. Lei XUE as a non-executive director of the Company, with effect from the date of 2026 AGM for an initial term of three years, and to authorise the board of directors of the Company to fix her remuneration and to enter into a letter of appointment with her.	288,465,357 (100.000000%)	0 (0.000000%)
3.	To re-appoint Ernst & Young as auditor of the Company and to authorise the board of directors to fix its remuneration.	288,465,357 (100.000000%)	0 (0.000000%)
4.	To give a general mandate to the directors of the Company to buy back shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of the passing of this resolution.	288,465,357 (100.000000%)	0 (0.000000%)
5.	To give a general mandate to the directors of the Company to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of the passing of this resolution.	288,465,357 (100.000000%)	0 (0.000000%)
6.	To extend the general mandate granted to the directors of the Company to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares bought back by the Company under the general mandate in Resolution (4).	288,465,357 (100.000000%)	0 (0.000000%)

Note:

- The full text of the above resolutions numbered 4 to 6 were set out in the Notice of 2026 AGM.

As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 6, all resolutions were duly passed as ordinary resolutions.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Upon approval at the 2026 AGM, Ms. Lei XUE (“**Ms. Xue**”) has been appointed as a non-executive Director with effect from the conclusion of the 2026 AGM. For the biographical details of Ms. Xue and other information disclosed as required by Rule 13.51(2) of the Listing Rules, please refer to the Circular. As at the date of this announcement, there has been no change of such information.

Save as disclosed in this announcement and the Circular, the Board is not aware of any other matter in relation to the appointment of Ms. Xue as a non-executive Director which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules and any other matter that needs to be brought to the attention of the Shareholders.

The Board sincerely welcomes Ms. Xue to join the Board.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 12 June 2026

As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Ms. Lei XUE, Ms. Xiaosu WANG and Dr. Jianmin ZHANG, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE, Ms. Chi Sau Giselle LEE and Mr. Nan SHEN.